

# Gerrit H Gielen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3691766/publications.pdf>

Version: 2024-02-01

20  
papers

510  
citations

840776

11  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3K27M Mutant Diffuse Midline Glioma. <i>Clinical Neuroradiology</i> , 2022, 32, 249-258.	1.9	8
2	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	4.2	22
3	DCE-MRI in Glioma, Infiltration Zone and Healthy Brain to Assess Angiogenesis: A Biopsy Study. <i>Clinical Neuroradiology</i> , 2021, 31, 1049-1058.	1.9	10
4	Diagnosis of Pseudoprogression Following Lomustine/Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. <i>Clinical Cancer Research</i> , 2021, 27, 3704-3713.	7.0	19
5	Challenging Implications of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids Syndrome with an Atypical Presentation: Report of Two Cases. <i>World Neurosurgery</i> , 2020, 143, 507-512.e1.	1.3	5
6	Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells. <i>Cell Death and Disease</i> , 2020, 11, 673.	6.3	36
7	Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. <i>EBioMedicine</i> , 2020, 59, 102962.	6.1	31
8	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. <i>Clinical Epigenetics</i> , 2020, 12, 94.	4.1	26
9	Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. <i>EBioMedicine</i> , 2020, 52, 102647.	6.1	38
10	PDGFRB mutation-associated myofibromatosis: Response to targeted therapy with imatinib. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 1895-1897.	1.2	14
11	The ERICA Score: An MR Imaging-based Visual Scoring System for the Assessment of Entorhinal Cortex Atrophy in Alzheimer Disease. <i>Radiology</i> , 2018, 288, 226-333.	7.3	33
12	Meningioma assessment: Kinetic parameters in dynamic contrast-enhanced MRI appear independent from microvascular anatomy and VEGF expression. <i>Journal of Neuroradiology</i> , 2018, 45, 242-248.	1.1	7
13	Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. <i>Neuro-Oncology</i> , 2018, 20, 123-131.	1.2	184
14	Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2018, 53, 255-258.	1.5	1
15	A suggestion to introduce the diagnosis of diffuse midline glioma of the pons, H3 K27 wildtype (WHO) Tj ETQq1_1 0.784314 rgB	7.7	13
16	Intravoxel incoherent motion MRI in the brain: Impact of the fitting model on perfusion fraction and lesion differentiability. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1187-1199.	3.4	32
17	Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. <i>Journal of Neuro-Oncology</i> , 2017, 133, 155-163.	2.9	6
18	Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. <i>European Journal of Cancer</i> , 2017, 81, 1-8.	2.8	4

#	ARTICLE	IF	CITATIONS
19	New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. <i>Neuroradiology</i> , 2017, 59, 1223-1231.	2.2	12
20	Altered splicing leads to reduced activation of CPEB3 in high-grade gliomas. <i>Oncotarget</i> , 0, 7, 41898-41912.	1.8	7